AstraZeneca Plc (AZN)

53.87
1.10 2.10
NYSE : Health Technology
Prev Close 55.00
Open 54.59
Day Low/High 53.76 / 55.27
52 Wk Low/High 36.15 / 57.44
Volume 4.46M
Avg Volume 5.23M
Exchange NYSE
Shares Outstanding 2.62B
Market Cap 140.76B
EPS 0.50
P/E Ratio 24.54
Div & Yield 1.37 (2.48%)
Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector

Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector

I continue to see these names as bargains in the biotech and biopharma space.

Small Cap Biotech Bargains

Small Cap Biotech Bargains

Here are 2 small caps I continue to see as bargains in this space.

4 Great Dividend Stocks That Always Remember to Say 'Thank You': Market Recon

4 Great Dividend Stocks That Always Remember to Say 'Thank You': Market Recon

These dividend payers compete in businesses that I'm interested in and believe in -- and they pay me to own the shares.

Watch Oncology Stocks Ahead of 2 Big Events

Watch Oncology Stocks Ahead of 2 Big Events

Data and industry conferences will likely be catalysts for shares in the space.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

It's Been a Fine Earnings Season, but Here Come the Retailers: Market Recon

It's Been a Fine Earnings Season, but Here Come the Retailers: Market Recon

Surviving the age of Amazon is all there is to retailers' earnings.

Geron Shares Rise on Fast Track Designation -- Biotech Movers

Geron Shares Rise on Fast Track Designation -- Biotech Movers

The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.

3 Small Biotech Stocks Insiders Are Buying

3 Small Biotech Stocks Insiders Are Buying

Verastem Inc., Pieris Pharmaceuticals and Intra-Cellular Therapies all have promising products.

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.

These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course

This week's bullish and bearish reversal patterns.

AstraZeneca Shares Sink on Lackluster Mystic Drug Results

AstraZeneca Shares Sink on Lackluster Mystic Drug Results

AstraZeneca shares are tanking.

China Was Right to Walk Away From Failed U.S. Trade Talks

China Was Right to Walk Away From Failed U.S. Trade Talks

The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.

These 3 Small Biotechs Have a Healthy Shot

These 3 Small Biotechs Have a Healthy Shot

Several firms hiked price targets on Portola into the $70s this week.

Give These 3 Small Biotechs a Shot

Give These 3 Small Biotechs a Shot

Several firms hiked price targets on Portola into the $70s this week.

Wake Up Wall Street: U.K. Prime Minister Theresa May Takes on Tech Companies

Wake Up Wall Street: U.K. Prime Minister Theresa May Takes on Tech Companies

U.K. Prime Minister Theresa May says technology companies have to do more to combat hate speech.

Closing Bell: GlobalStar Soars on Deal Considerations; Retail Sinks Wall Street Again

Closing Bell: GlobalStar Soars on Deal Considerations; Retail Sinks Wall Street Again

Stocks end the session mixed after Nordstrom and J.C. Penney become the latest retail names to report on a weak quarter.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Keep Trading AstraZeneca From the Long Side

Keep Trading AstraZeneca From the Long Side

The stock is headed toward a bullish golden cross.

Closing Bell: Blizzard Conditions Mute Trading Activity; AstraZeneca Jumps

Closing Bell: Blizzard Conditions Mute Trading Activity; AstraZeneca Jumps

Stocks declined on Tuesday as wild weather stifled activity and led to low volume.

Egalet Makes Friday's Biotech Mailbag

Egalet Makes Friday's Biotech Mailbag

Why the name is sagging, and what it will take to spur the sector higher.

Cramer: Don't Give the Fed Credit

Cramer: Don't Give the Fed Credit

Most of the 10 best stocks of the bull market did it their way.

Wake Up Wall Street: Donald Trump to Address Congress

Wake Up Wall Street: Donald Trump to Address Congress

U.S. stock futures and shares in Europe and Asia trade mixed Tuesday ahead of Donald Trump's first speech to a joint session of Congress.

Global Financial News: Nikkei 225 Snaps Losing Streak

Global Financial News: Nikkei 225 Snaps Losing Streak

Markets in Asia attempted to bridge the gap between U.S. and European markets overnight before paring gains as the session wound to a close

AstraZeneca Has Started a Turnaround

AstraZeneca Has Started a Turnaround

The old saying that volume precedes price could be playing out

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.